(Q48314259)

10 February 2018

title

Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials (English)

1 reference

10 February 2018

1 reference

1

David A Reardon

1 reference

10 February 2018

2

Hideho Okada

1 reference

10 February 2018

publication date

24 February 2015

1 reference

10 February 2018

Journal of Neuro-Oncology

published in

1 reference

10 February 2018

volume

123

1 reference

10 February 2018

issue

3

1 reference

10 February 2018

page(s)

339-346

1 reference

10 February 2018

https://scigraph.springernature.com/pub.10.1007/s11060-015-1748-7

exact match

0 references

cites work

Cancer immunotherapy: moving beyond current vaccines

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Chimeric antigen receptor T cells for sustained remissions in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Dual role of immunomodulation by anticancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Immunologic correlates of the abscopal effect in a patient with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Bevacizumab plus ipilimumab in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Improved Endpoints for Cancer Immunotherapy Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

A clinical development paradigm for cancer vaccines and related biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-015-1748-7

Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25707876

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25707876

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25707876

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-015-1748-7

1 reference

10 February 2018

1 reference

10 February 2018